Omalizumab in chronic inducible urticaria: a real-life study of efficacy, safety, predictors of treatment outcome and time to response

421. Yu, M., Terhorst-Molawi, D., Altrichter, S., Hawro, T., Chen, Y.-D., Liu, B., Song, X.-T., Zhao, Z.+*, and Maurer, M.+*: Omalizumab in chronic inducible urticaria: a real-life study of efficacy, safety, predictors of treatment outcome and time to response. Clin. Exp. Allergy 2021: 51; 730-734. IF: 5.40

o.421